World's First ConSpeed® Automated Ultrasound Contrast Injection System by Wuyou Tiaodong Receives Market Approval

Sep 20, 2025 17:31 CST Updated 17:31

WYTD

Developer of Cardiac Disease Diagnosis and Treatment Equipment

Reprinted from:Enterprise Information

Recently, WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. (hereinafter referred to as "WYTD Medical") independently developed

ConSpeed®Automatic Contrast-Enhanced Ultrasound Injection System

Officially Obtained

Medical Device Registration Certificate

(Registration Certificate No.: Yue Medical Device Registration Approval 20252061271). The successful approval of this product marks

World's First Automatic Contrast-Enhanced Ultrasound Injection System

Officially launched, which not only pioneered the diagnosis of Patent Foramen Ovale (PFO)

Automation, Standardization, Normalization

A new era has begun, laying a solid foundation for the development of intelligent and precise diagnosis and treatment in the field of structural heart disease.

AsThe World's FirstThe automatic ultrasound contrast injection system, ConSpeed®, developed based on the bubble test, has been designed with full consideration of clinical application scenarios. Its scope of application includes: use in conjunction with disposable masks, disposable contrast injectors, and accessories for trans-thoracic echocardiography acoustic contrast bubble tests or contrast-enhanced transcranial Doppler ultrasound acoustic contrast bubble tests to prepare and inject mixed (activated) saline solution. Additionally, the system is equipped with a built-in blood pressure monitoring module that can monitor the patient's pulse and non-invasive blood pressure in real time, providing dual safety assurance during the examination process.

In terms of structural configuration, ConSpeed®Composed of a main unit, touch screen, and air-blowing handle, it can be paired with optional accessories such as a trolley, foot switch, and blood pressure cuffs (adult/child) to meet the needs of different clinical scenarios. Currently, the product is available in two model specifications, BS-1 and BS-2, offering flexible operation while accommodating the usage habits and functional expansion requirements of different departments.

Patent Foramen Ovale (PFO)It is a common congenital cardiac anomaly, with an incidence rate of approximately 25% in the adult population. Relevant studies have shown that PFO is associated withCryptogenic Stroke, Migraine with Aura, Paradoxical Embolism, Decompression SicknessAndSupine Respiratory-Orthostatic Hypoxemia Syndromeclosely related to a variety of diseases. Therefore, the precise diagnosis of PFO is of great clinical significance in reducing the potential risks for patients. Among the existing examination methods, the bubble study isCommon means for screening right-to-left shunt (RLS), but it has multiple limitations: on one hand, it relies on manually mixing air, blood, and saline, causing uneven bubble mixing, unstable test results, excessive dependence on personal experience, poor repeatability, and uncontrollable bubble size; on the other hand, patient cooperation is required during the detection process.Valsalva Maneuver, but because most patients have difficulty mastering the key points or perform movements incorrectly, it often affects the examination results and interpretation, further limiting the standardization and accuracy of PFO diagnosis.

ConSpeed, independently developed by WYTD Medical Technology (Shenzhen) Co., Ltd.®The automatic ultrasound contrast injection system is precisely designed to address the aforementioned pain points. Through full-process automation and intelligent design, the system achieves

Highly uniform bubble mixing, standardized detection operations, and fully automated processes

, which not only comprehensively improves the accuracy and repeatability of PFO diagnosis but also significantly optimizes the clinical operation experience. More importantly, ConSpeed®Innovatively adopt

Exhalation Trigger Mode

, replacing the traditional Valsalva maneuver,

Greatly reduces the requirement for patient cooperation, making the examination process simpler and more comfortable, and also making the result interpretation more objective and reliable.

. Compared with the traditional manual foam test, ConSpeed®Significant System Advantages:

Automated mixing of foaming solution, with uniform and stable bubbles

ConSpeed^®By precisely controlling the extraction volume, mixing ratio, injection speed, and frequency, the system achieves fully automatic and uniform mixing and injection of the foaming solution, ensuring consistent microbubble size and stable distribution, effectively reducing the risk of false negatives or false positives, and significantly improving detection accuracy.

Standardized operations eliminate human variations

Full-process automation eliminates subjective errors caused by manual foaming, achieving high consistency in results across different patients and batches, providing clinicians with stable and comparable testing basis.

Reduce Patient Burden, Improve Testing Consistency

ConSpeed^®By innovating a breath-triggering mechanism to replace the traditional Valsalva maneuver, detection can be completed with just mild exhalation. This design not only significantly reduces reliance on patient cooperation, avoiding result deviations caused by improper Valsalva maneuvers, but also enhances the controllability and repeatability of the test, providing more stable and reliable data support for clinical use.

Improve Detection Efficiency

ConSpeed^®The fully automated design significantly simplifies the testing process, allowing a single medical staff member to independently complete the operation. This not only effectively reduces labor costs and eases the manual workload but also markedly improves the overall testing efficiency.

ConSpeed®The approval of the automatic ultrasound contrast injection system is not only an important milestone in WYTD's medical innovation journey, but also marks the official entry of PFO diagnosis into an automated, standardized, and regulated phase. In the future, this system will play a crucial role in key areas such as precise preoperative screening and postoperative efficacy evaluation, promoting the comprehensive advancement of structural heart disease diagnosis and treatment into a new era of greater intelligence and high-quality development.

Company Profile

[Company Profile]

WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. was established in 2021 as a national high-tech enterprise focusing on the diagnosis and treatment of pan-vascular diseases. The current product line mainly revolves around PFO, aiming to provide a comprehensive set of diagnostic and therapeutic solutions for PFO. The company consistently upholds the core values of "innovation, collaboration, hard work, and win-win," adhering to the noble mission of "maximizing patients' quality of life and perfecting the last line of defense for life." It is committed to offering innovative medical device solutions to patients and aspires to become a leader in innovative cardiac medical devices within ten years.

Contact Immediately: Mr. Guo 18007176716

END